KEYNOTE-826 trial met its dual primary endpoints
Survival benefit with first-line pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer
Novel immunotherapy-containing strategies look promising in microsatellite stable mCRC
Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials
Positive preliminary data with the T-cell receptor fusion construct, gavocabtagene autoleucel
Manageable toxicity profile and signs of clinical benefit seen with gavocabtagene autoleucel in treatment-refractory mesothelin-expressing solid tumours
Novel approaches to improve immunotherapy and more news on synthetic lethality
The ESMO Congress 2021 has started today with three sessions on developmental therapeutics, including immunotherapy. The overarching theme in these sessions is the improvement of checkpoint inhibitor-based immunotherapy and a new flavour of synthetic lethality in molecularly pre-defined solid tumours.
Women receiving immunotherapy may be at higher risk of adverse events than men
Prospective evidence from a multicentre study support the need for a more personalised immuno-oncology approach based on sex and gender differences
Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
